

# DRIVING INNOVATION TO SAVE THE LIVES OF WOMEN AND CHILDREN



PATH is the leader in global health innovation. An international nonprofit organization, we save lives and improve health, especially among women and children. We accelerate innovation across five platforms—vaccines, drugs, diagnostics, devices, and system and service innovations—that harness our entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, we take innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. Together, we deliver measurable results that disrupt the cycle of poor health.



## PATH by the numbers

**150 million**

Average number of people PATH and our partners reached annually over the past five years

**75+**

Technologies advanced in partnership with the US government since 2012

**80+**

Tools and technologies in our development pipeline

**100+**

System and service innovation projects in our portfolio

**1,400+**

Number of PATH staff

**2,400+**

Donors and funders supporting PATH

**2,000+**

Partner organizations around the world

**20**

Countries in Africa, Asia, Europe, Latin America, and North America that are home to PATH offices

## PATH'S PLATFORMS: INNOVATION AND IMPACT



Vaccines

Accelerate the development and delivery of vaccines for diarrheal disease, influenza, Japanese encephalitis, malaria, meningitis, pneumococcal disease, polio, and other vaccine-preventable diseases

230 million+ people vaccinated against Japanese encephalitis since 2015.

More than 235 million Africans immunized against meningitis A since 2010. Meningitis A has virtually disappeared in immunized populations.

Severe rotavirus diarrhea reduced by 56 percent in new rotavirus vaccine trial.

Most clinically advanced malaria vaccine candidate (RTS,S) recommended by the WHO for large-scale pilot implementations.



Drugs

Develop and introduce affordable drugs for diseases that disproportionately affect people in low-income countries, including drugs to treat or prevent diarrhea, HIV/AIDS, malaria, and neglected tropical diseases

More than 50 million treatments of antimalarial medication developed with a new semisynthetic form of artemisinin and delivered to malaria-endemic African countries since 2015.

An estimated 1 million newborns could be saved over the next 15 years by scaling up use of an umbilical cord antiseptic that costs less than 50 cents a dose.



Diagnostics

Develop and introduce fast, accurate diagnostic technologies tailored to low-resource settings to detect and track diseases, including cervical cancer, diabetes, HIV/AIDS, malaria, neglected tropical diseases, and tuberculosis

A new 20-minute diagnostic tool to detect river blindness is now available to help the nearly 170 million people worldwide who are at risk of the disease.

185 million malaria strip tests have been used in clinics and hospitals in the developing world to provide same-day malaria test results.



Devices

Work with the people we serve to develop, adapt, and introduce health technologies that improve maternal, reproductive, and newborn health; nutrition; and water and sanitation

6 billion vaccine vial monitors have been used, helping to ensure vaccines are still potent when they are delivered.

More than 100 million of the compact, prefilled, autodisable injection systems developed by PATH have been distributed to help boost immunization rates worldwide.



System and Service Innovations

Collaborate with country partners using a suite of system and service innovations to strengthen health systems, encourage healthier behaviors, and increase access to affordable solutions

5,000+ health volunteers in the DRC trained since 2009 to mobilize communities and reach the most vulnerable impacted by HIV/AIDS.

In Zambia, malaria parasite prevalence in young children decreased by nearly 32 percent in six years.

30 percent decrease in mortality rates of people co-infected with tuberculosis and HIV in Ukraine, thanks to earlier treatment.

More than 4.3 million Kenyans reached by integrated services for HIV/AIDS, malaria, maternal and child health, and tuberculosis.

